NCT05200286View on ClinicalTrials.gov

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

December 13, 2022

Study Completion Date

December 13, 2022

Conditions

Renal Impairment

Interventions

DRUG

Olorofim

Single oral dose

Trial Locations (1)

32808

Omega Research, Orlando

Sponsors

Lead Sponsor

F2G Biotech GmbH

All Listed Sponsors

lead

F2G Biotech GmbH

INDUSTRY

NCT05200286 - A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment | Biotech Hunter | Biotech Hunter